Clinical Trials Browser

Phase 3 × Melanoma × pembrolizumab × Clear all

NCT02506153 2026-03-18

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Melanoma

NCT02362594 2026-03-05

MK-3475-054

Phase 3 Active not recruiting

1,019 enrolled 16 charts 1 FDA

Melanoma

NCT04657991 2026-03-02

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Phase 3 Recruiting

Melanoma, Nevus, Blue

NCT03820986 2026-02-09

LEAP-003

Phase 3 Completed

674 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04889118 2025-12-23

LEAP-003

Phase 3 Completed

131 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05665595 2025-10-15

KEYVIBE-010

Phase 3 Completed

1,594 enrolled 12 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05933577 2025-09-24

V940-001

Phase 3 Active not recruiting

Melanoma

NCT05155254 2025-08-28

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Phase 3 Active not recruiting

Melanoma

NCT02752074 2025-08-24

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Phase 3 Completed

706 enrolled 17 charts

Melanoma

NCT05727904 2025-07-08

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Phase 3 Recruiting

Melanoma, Skin Neoplasms

NCT05608291 2025-05-13

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT03553836 2024-11-29

KEYNOTE-716

Phase 3 Active not recruiting

976 enrolled 15 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT06320353 2024-03-20

Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma

Phase 3 Active not recruiting

Melanoma, Neoplasms

NCT05986331 2023-09-21

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

Phase 3 Unknown

Melanoma

NCT01866319 2020-06-02

MK-3475-006

Phase 3 Completed

834 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma